NAD+ Compounded Drug Recall for Manufacturing Quality Control Violations
Olympia Compounding Pharmacy is recalling NAD+ lyophilized powder (16,329 vials nationwide) due to failure to properly investigate environmental and personnel monitoring violations in manufacturing.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is a compounded injectable drug with CGMP violations involving failure to properly investigate environmental monitoring for a sterile product. No illnesses or injuries have been reported, and the hazard is theoretical. This meets the rubric criterion of 'risk-of-harm products where injury has not yet been reported.'
Plain-English summary
Olympia Compounding Pharmacy is recalling NAD+ Nicotinamide Adenine Dinucleotide lyophilized powder for reconstitution due to Current Good Manufacturing Practice (CGMP) deviations. Prior to October 1, 2021, the facility failed to properly investigate environmental and personnel monitoring Out of Action Limit (OOAL) excursions.
The affected product is a 500 mg per vial, multi-dose injectable powder distributed nationwide across the United States. This recall affects 16,329 vials with lot codes E24026, E42112, E48024, F24014, G48028, H24016, H42010, H48030, and I47003, each with corresponding Beyond Use Dates ranging from February 2022 through August 2022.
Patients who received this product should contact their physician or pharmacist to discuss this recall.
The recalled product
- Product
- NAD+ Nicotinamide Adenine Dinucleotide Lyophilized powder for reconstitution, Multi-Dose 500 mg Per Vial, Rx Only, Olympia Pharmaceuticals 6700 Conroy Rd., Ste. 155, Orlando, FL 32835. NDC 73198-0083-00
- Category
- Drug — Compounded Injectable
- Affected units
- 16,329
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (9)
- Lots: E24026 BUD: 5/26/2022
- E42112 BUD: 5/12/2022
- E48024 BUD: 2/2/2022
- F24014 BUD: 6/14/2022
- G48028 BUD: 7/28/2022
- H24016 BUD: 8/16/2022
- H42010 BUD 8/10/2022
- H48030 BUD: 8/11/2022
- I47003 BUD: 8/11/2022
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 34 recalled by Olympia Compounding Pharmacy dba Olympia Pharmacy under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 34 products in this recall →Related recalls
Same manufacturer · Olympia Compounding Pharmacy dba Olympia Pharmacy
See all →- HighLidocaine 2% injectable solution recalled for lack of sterility assurance
FDA (Drugs) · 2022-06-01
- HighFDA Recalls Compounded Papaverine Injection Due to Sterility Assurance
FDA (Drugs) · 2022-06-01
- HighFDA Recalls Testosterone Cypionate Injection Vials for Lack of Sterility Assurance
FDA (Drugs) · 2022-06-01
- HighCompounded pharmaceutical vials recalled due to sterility assurance failure
FDA (Drugs) · 2022-06-01
- HighOndansetron Hydrochloride vials recalled due to sterility assurance concerns
FDA (Drugs) · 2022-06-01
Same hazard · cgmp violation
See all →- Moderatevite20 Antifungal Cream recalled due to stability testing deviations
FDA (Drugs) · 2026-07-08
- ModerateNeuroquell products recalled over current good manufacturing practice violations
FDA (Drugs) · 2025-09-17
- ModerateOptim V Anti-Itch Cream Recalled for Current Good Manufacturing Practice Deviations
FDA (Drugs) · 2025-05-28
- ModerateNature Mint Anticavity Fluoride Toothpaste Recalled for CGMP Deviations
FDA (Drugs) · 2025-05-28
- ModerateRapidol Hydrocortisone 1% Anti-Itch Cream Recalled for CGMP Deviations
FDA (Drugs) · 2025-05-28